Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:

Spatial Surgery

Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation. This 510(k)-pending technology called the TESSA^? Spatial Surgery System (Tracking Enabled Spatial Surgery Assistant) plans to combine personalized operative planning with a real-time, tracking enabled device using advanced imaging and augmented reality guidance to assist a surgeon in decision making. Learn more at www.spatialsurgery.com

CARTIHEAL^? AGILI-C^? Cartilage Repair Implant

Smith+Nephew’s CARTIHEAL AGILI-C Cartilage Repair Implant is an FDA approved device that was previously granted breakthrough designation and is now evolving the cartilage repair landscape. The unique properties of the implant enable physicians to surgically treat patients that previously had no access to cartilage repair procedures.^1-3 In a large randomized controlled trial, when compared to the surgical standard of care,^* the CARTIHEAL AGILI-C implant demonstrated:

• Proven clinical superiority: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee function, pain relief, and mobility improvements over a 4-year period.^{1,4 **}
• Significantly lower risk of TKA or osteotomy: Patients’ risk of additional knee reconstruction/realignment surgery at 4 years.⁴
• Different patient profiles – same great results: The scaffold treats a broad group of patients across age, lesion size, and presence of osteoarthritis while delivering clinically meaningful results.^{1,4, **}

The use of the CARTIHEAL AGILI-C Implant in the presence of osteoarthritis will be featured during OrthoDome at AAOS on Wednesday, March 12, from  11:16-11:31 am PST. You can learn more by visiting the CARTIHEAL AGILI-C  webpage here.

REGENETEN^? Bioinductive Implant

The REGENETEN Bioinductive Implant is a scaffold made from highly purified type I collagen fibers and has changed the way surgeons treat tendon injuries for more than ten years.^5-8 Clinical studies in rotator cuff repair have demonstrated results that surpass the current standard of care:

• 3x reduction in the risk of re-tear in a randomized controlled trial versus standard repair alone augmenting repair of medium-to-large full-thickness tears (at 1-year).^9***
• Accelerated recovery and return to activity when used as an isolated treatment (compared with takedown and suture anchor repair),^10,11 while leading to consistent tendon healing for partial-thickness tears.^9,12
• Well established technique used in >150,000 patients, with a proprietary delivery and fixation system resulting in a 15-minute procedure.⁹

In addition to continued value in rotator cuff repair, usage of the REGENETEN Implant continues to increase in tendons around the body, including those in the hip, knee, and foot & ankle, where surgeons recognize its potential to improve tendon healing. You can learn more by visiting the REGENETEN webpage here.

To learn more about Smith+Nephew’s Sports Medicine joint repair solutions and enabling technologies, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego March 11-13, 2025, or visit www.smith-nephew.com.

- ends –

 

Media Enquiries 

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

 

* Debridement or microfracture

**  Over a 2- and 4-year follow-up

***  Re-tear: 8.3% vs 25.8%; Relative risk=0.32 [95% Confidence Interval 0.13-   

       0.83]; p=0.0106.

 

  References

1. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967
2. Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598
3. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81
4. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126
5. Bokor DJ, et al. Muscles Ligaments Tendons J. 2016;6(1):16-25.
6. Warren JR, et al. J Shoulder Elbow Surg. 2024;33(11):2515-2529
7. Bokor DJ, et al. Muscles Ligaments Tendons J. 2015;5(3):144-150.
8. Smith+Nephew 2020 REGENETEN Collagen Implant Physical Characteristics. Internal Report Internal Report. 15009769
9. Ruiz Ibán MÁ, et al. Arthroscopy. 2024;40(6):1760-1773.
10. Camacho Chacón JA, et al. J Shoulder Elbow Surg. 2024;33(9):1894-1904.
11. Bushnell BD, et al. Orthop J Sports Med. 2021;9(8):23259671211027850.
12. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

 

^? Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.